Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or California for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to California only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. California (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Ravi Rao (NPI 1417927054)

Field	Value
Entity Type	Individual
Organization	Ravi Rao
Address	7130 N Millbrook Ave
City	Fresno
State	CA
ZIP	93720
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	January 25, 2006

Payer Source	Total Paid
Medicare	$6.6M
Medicaid	$0

Key Findings

The provider’s Medicare billing mix is characteristic of an oncology infusion practice that focuses on high-cost biologics and immunotherapies alongside imaging and chemotherapy administration. Top revenue drivers include J9299 ($1.2M revenue, 19.5% of Medicare revenue), J9144 ($690.8K, 11.4%), and J9271 ($576.2K, 9.5%), and the presence of 96413 and PET/CT codes such as 78815 ($538.5K, 8.9%) indicates routine on-site or closely coordinated infusion and diagnostic imaging services supporting cancer care. This combination of drug, infusion/procedure, and imaging codes points to an integrated outpatient oncology service line rather than a pure diagnostic or surgical practice.

Revenue concentration is high: the precomputed top 3 Medicare codes account for 40.4% of this provider’s total Medicare revenue, and total Medicare revenue is $6.6M. That concentration underscores dependence on a small set of high-revenue oncology agents (notably J9299, J9144, J9271) for a large share of overall Medicare inflows, which could make revenue sensitive to changes in utilization or reimbursement for those drugs.

Payer mix is effectively single-payer Medicare: total Medicare revenue is $6.6M while there is no Medicaid billing on file (none below). This means the provider’s publicly reported revenue exposure is concentrated in Medicare patients, with no documented Medicaid volume to diversify public-payer risk.

Competitive standing varies by code: the provider is a national high-volume dispenser of nivolumab (J9299 ranks #13 of 505, 98th percentile; noted as notably above typical national volume) and a high-volume user of daratumumab (J9144 ranks #63 of 615, 90th percentile), while pembrolizumab (J9271) volume is more typical (ranks #806 of 1841, 55th percentile). In practice this suggests strong competitive presence for specific immunotherapy agents nationally, but not uniformly across all comparable biologics.

Multiple codes appear as statistical outliers in national comparisons, reflecting atypical volume patterns that shape overall activity. Examples include J1449 (rank #4 of 161, 98th percentile; labeled an extreme outlier), J0881 (rank #3 of 1114, 100th percentile; extreme outlier), J1439 (rank #13 of 1209, 99th percentile; extreme outlier), and office E/M codes 99214 (rank #1894 of 479517, 100th percentile; extreme outlier) and 99215 (rank #742 of 145531, 99th percentile; extreme outlier). These extreme and near‑extreme positions indicate unusually large volumes for certain low-unit-payment infusions and for higher-level office visits relative to peers.

Imaging and diagnostic CPT/HCPCS show meaningful contribution to revenue and suggest operational integration or tight referral relationships with imaging services. PET/CT code 78815 generated $538.5K (8.9% of Medicare revenue) with 398 claims, and A9552 generated $119.7K (2.0%) with 423 claims, supporting a care model that pairs systemic therapy with advanced imaging to guide treatment. For payers and network planners, that pattern flags a practice with both therapeutic and diagnostic capacity that can influence episode cost and care coordination.

Operational profile implied by claim counts and per-claim payments points to high throughput infusion activity: for example, J9299 shows 49.5K claims at $24 avg paid/claim ($1.2M revenue), J9144 18.2K claims at $38 avg ($690.8K), and J9271 13.4K claims at $43 avg ($576.2K). The combination of very large claim volumes with modest per-claim payments for many infused agents is consistent with an infusion-center throughput model where revenue depends on volume of administrations rather than a small number of very high unit-dollar claims.

The provider’s NPI tenure (enumerated 2006-01-25, ~20 years ago) signals a long-established practice footprint. Combined with the concentrated Medicare revenue and the code-level volume outliers, this longevity suggests an entrenched oncology service line with sustained patterns of high-volume biologic administration and frequent office encounters over time.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

100 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9299	Injection, nivolumab, 1 mg	49,480	$20	$1.2M
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	18,180	$40	$690.8K
J9271	Injection, pembrolizumab, 1 mg	13,400	$40	$576.2K
78815	PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.…	400	$1,350	$538.5K
J1930	Injection, lanreotide, 1 mg	7,200	$50	$324K
J0897	Injection, denosumab, 1 mg	17,160	$20	$308.9K
J1449	Injection, eflapegrastim-xnst, 0.1 mg	10,160	$30	$264.3K
Q5126	Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg	4,360	$60	$248.5K
J9173	Injection, durvalumab, 10 mg	3,870	$60	$240.2K
J0881	Injection, darbepoetin alfa, 1 microgram (non-esrd use)	119,300	$1	$238.6K

Showing 1–10 of 100

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 100 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. California Distribution

Ravi Rao — 9 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — California

Full comparison — all codes billed, vs. state median

100 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	64	140	13,100	$40	$653.5K
J9144	13	40	13,860	$40	$631.4K
J9299	4	40	21,000	$20	$538.5K
J1930	3	10	7,200	$40	$477.9K
J1569	14	40	4,560	$40	$303.5K
J9173	3	10	4,260	$60	$298.9K
J1449	2	20	6,340	$30	$167.2K
Q5126	2	10	2,390	$60	$165.3K
88185	19	40	1,560	$20	$139.2K
78815	47	590	70	$740	$104.1K

Showing 1–10 of 100

Related Providers

Other providers that share a Tax Identification Number (TIN) with Ravi Rao, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Daniel Watrous	CA	Rheumatology Physician	$4M	$5M
John Saito	CA	Pediatric Pulmonology Physician	$468.7K	$6.5M
Dexter Estrada	CA	Hematology & Oncology Physician	$5.6M	$0
Sachin Gupta	CA	Hematology & Oncology Physician	$5.3M	$0
Humberto Villalvazo	OR	Family Medicine Physician	$4.3M	$0
Kishore Sehgal	CA	Hematology & Oncology Physician	$4.1M	$0
Abdul Haseeb	CA	Hematology & Oncology Physician	$4M	$0
Hanumandla Reddy	CA	Specialist	$3.8M	$8.8K
Steven Hager	CA	Hematology & Oncology Physician	$3.6M	$0
Amardeep Aulakh	CA	Internal Medicine Physician	$3.5M	$0

Nearby Providers

Other providers in the same ZIP code as Ravi Rao, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Sierra Pacific Surgery Center LLC	CA	Ambulatory Surgical Clinic/Center	$4.3M	$0
George Bertolucci	CA	Ophthalmology Physician	$3.5M	$0
Leonard Hackett	CA	Hematology & Oncology Physician	$3.3M	$0
Daniel Prescott	CA	Ophthalmology Physician	$3.3M	$0
Joseph Pascuzzo	CA	Hematology & Oncology Physician	$3.2M	$0
William Jawien	CA	Hematology & Oncology Physician	$3.2M	$0
Sumeer Thinda	CA	Ophthalmology Physician	$2.7M	$0
Dalpinder Sandhu	CA	Cardiovascular Disease Physician	$2.7M	$0
Michael Krueger	CA	Cardiovascular Disease Physician	$2.7M	$0
Himmat Gill	CA	Rheumatology Physician	$2.5M	$0

Ravi Rao — Billing Profile & Reimbursement Data

Sign up for Ravi Rao — Billing Profile & Reimbursement Data policy alerts

Ravi Rao — Billing Profile & Reimbursement Data

Sign up for Ravi Rao — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References